Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- Pliant Therapeutics readies IPOon May 11, 2020 at 9:59 am
Pliant Therapeutics (PLRX) has filed a preliminary prospectus for an $86M IPO.The South San Francisco, CA-based biopharmaceutical firm develops treatments for fibrosis (scarring). Lead candidate is PL ...
- Third Rock-backed biotech Pliant Therapeutics files for an $86 million IPOon May 11, 2020 at 6:28 am
The article Third Rock-backed biotech Pliant Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Investment ...
- Bay Area biotech files plans for IPO as it works to treat lung-scarring diseaseon May 11, 2020 at 5:19 am
A Bay Area biotech that's developing treatments for #fibrosis has filed plans to raise up to $86 million in an #IPO.
- Relief Therapeutics Announces Filing of IND for Phase 2/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injuryon May 11, 2020 at 12:23 am
Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU care -- RLF-100, a patented ...
- Paul Marks, Past President of MSKCC, Dieson May 8, 2020 at 8:34 am
A cancer researcher with a talent for leadership, Marks turned the Memorial Sloan Kettering Cancer Center into one of the world's foremost oncology research institutions.
- Idiopathic Pulmonary Fibrosis Treatment Market is Set to Surge with Rise in Fitness and Health Awareness by 2027on May 8, 2020 at 4:20 am
The global Idiopathic Pulmonary Fibrosis Treatment Market is projected to reach more than US$ 4.2 Billion By 2027 with a CAGR of 11.6% during the forecast period, As per the research done by Acumen ...
- Idiopathic Pulmonary Fibrosis Treatment Market Global Research and Clinical Survey Report 2020 to 2026on May 5, 2020 at 1:12 am
The report titled "Idiopathic Pulmonary Fibrosis Treatment Market" has recently added by MarketInsightsReports to get a stronger ...
- Survival After Acute Flares of Interstitial Lung Disease Varies by Fibrosis Type, Study Sayson May 2, 2020 at 4:14 am
Patient survival following acute exacerbation depended on the pulmonary fibrosis type of the patient, according to the paper.
- Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast-2030on April 30, 2020 at 10:01 am
Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast-2030 (Albany, US) DelveInsight launched a new report on Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and ...
via Bing News